Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.
Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.
Genprex, a clinical-stage gene therapy company (NASDAQ: GNPX), announced its participation in key investor and healthcare conferences in January 2022. CEO Rodney Varner and CMO Mark Berger will lead presentations at events including the HC Wainwright BIOCONNECT, Biotech Showcase, and the Precision Lung Cancer World R&D Summit. The CEO Roadshow presentation is scheduled for January 26, 2022. Genprex focuses on developing gene therapies for cancer and diabetes, utilizing their proprietary ONCOPREX® delivery system. REQORSA™, their lead candidate for lung cancer, has received Fast Track Designation from the FDA.
Genprex, Inc. (NASDAQ: GNPX) has expanded its research pipeline to include small cell lung cancer (SCLC) for its lead drug candidate, REQORSA™. SCLC accounts for 10-15% of the lung cancer market, while non-small cell lung cancer (NSCLC) represents 84%. The Chief Medical Officer noted that REQORSA might be effective due to low TUSC2 protein levels in SCLC. The company aims to address unmet medical needs in cancer treatments, potentially improving patient outcomes significantly.
Genprex, Inc. (NASDAQ: GNPX) announced that the FDA granted a second Fast Track Designation for its lead drug candidate, REQORSA Immunogene Therapy. This designation applies to the drug used in combination with Keytruda for patients with late-stage non-small cell lung cancer (NSCLC). Genprex plans to start the Acclaim-2 clinical trial in early 2022. As of Q3 2021, the Company had a strong cash position of $42 million, positioning it well for clinical development efforts in 2022.
Genprex, Inc. (NASDAQ: GNPX) announced its President and CEO, Rodney Varner, will present at the CEO Roadshow on November 17 at 11 a.m. ET. The webinar will focus on Genprex's innovative gene therapies targeting cancer and diabetes. Attendees will have an opportunity for questions post-presentation. The session will be recorded and accessible on Genprex’s website. Genprex specializes in advanced gene therapy solutions, including its lead product REQORSA™, aimed at treating non-small cell lung cancer.
Genprex, Inc. strengthens its leadership team by appointing Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer. These additions come as the company advances its Acclaim-1 and Acclaim-2 clinical trials for REQORSA, a systemic gene therapy targeting non-small cell lung cancer (NSCLC). Both leaders bring extensive experience in oncology and gene therapy, aiming to enhance Genprex's pipeline and clinical strategy. Additionally, they were granted stock options at an exercise price of $2.85.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that its President and CEO, Rodney Varner, will present at two upcoming investor conferences in September 2021.
The CEO Roadshow Webinar is scheduled for September 22, 2021, at 11:00 a.m. ET, while the Benzinga Healthcare Small Cap Conference takes place on September 29, 2021, at 1:15 p.m. ET.
These presentations will demonstrate Genprex's innovative therapies for cancer and diabetes and will be available for replay on their website.
Genprex, Inc. (NASDAQ: GNPX) has announced that its President and CEO, Rodney Varner, will participate in a webinar series with CEO Roadshow to present a company overview to investors each month from July to September 2021. Key dates include July 21, August 18, and September 22. The webinars will include a Q&A session and will be available for replay. Genprex focuses on developing gene therapies for cancer and diabetes, with its lead product, REQORSA™, undergoing evaluation for non-small cell lung cancer.
Genprex, Inc. (GNPX) announced FDA confirmation that all comments regarding its Acclaim-1 clinical trial protocol have been addressed. This Phase 1/2 trial evaluates REQORSA™ Immunogene Therapy combined with AstraZeneca's Tagrisso® for late-stage non-small cell lung cancer patients who have progressed after Tagrisso treatment. Genprex has engaged its first clinical site and aims to enroll 18 patients in Phase 1 and 74 in Phase 2. The trial’s primary endpoint is progression-free survival, with an interim analysis planned at 51 events.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, is participating in Noble Capital Markets' Virtual Roadshow on May 20, 2021. The event features a corporate presentation by President and CEO Rodney Varner and a Q&A session with analyst Robert LeBoyer. Registration is free for all investors. Genprex focuses on developing innovative therapies for cancer and diabetes, with its lead candidate, REQORSA™, targeting non-small cell lung cancer (NSCLC) and having received FDA Fast Track Designation. More information is available on their official website.
Genprex, Inc. (NASDAQ: GNPX), a gene therapy company focused on cancer and diabetes treatments, has announced its participation in several investor conferences throughout May. Presentations will be led by President and CEO Rodney Varner.
Key Events:
- Diamond Equity Emerging Growth Invitational: May 11, 11-11:25 a.m. ET
- Benzinga Small Cap Conference: May 14, 12:45-1:05 p.m. ET
- CEO Roadshow Webinar: Weekly on Thursdays from April 22 to June 10, 11-11:30 a.m. ET
Recordings will be available post-conference on Genprex's website.